Randy Schatz­man jumps to the helm of an­oth­er start-up; No­vo Nordisk vet lands top post at Macrophage Phar­ma

→ In biotech, long-term sur­vival in the ex­ec­u­tive ranks can de­pend a lot on the qual­i­ty of your con­nec­tions in the ven­ture/in­vest­ing side of the busi­ness.

So when Randy Schatz­man ex­it­ed Alder af­ter tak­ing the com­pa­ny from con­cep­tion to the thresh­old of a like­ly ap­proval for a new mi­graine ther­a­py, it was his re­la­tion­ship with long­time back­ers that led him to his new job as CEO of Bolt Bio­ther­a­peu­tics, an­nounced this week.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER